USPTO Examiner HILL MYRON G - Art Unit 1648

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18590312RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATIONFebruary 2024July 2024Allow510NoNo
18473720Mutated Glycoprotein of Vesicular Stomatitis VirusSeptember 2023February 2024Allow500NoNo
18464786PREFUSION RSV F PROTEINS AND THEIR USESeptember 2023December 2023Allow300NoNo
18335879METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZAJune 2023June 2024Allow1200YesNo
18335869METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZAJune 2023April 2024Allow1000NoNo
18335876METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZAJune 2023April 2024Allow1000NoNo
18308583PRE-FUSION RSV F ANTIGENSApril 2023March 2024Abandon1110NoNo
18173006RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAMEFebruary 2023September 2023Allow710YesNo
18058185SYSTEMS AND METHODS FOR THE PREPARATION OF VACCINES UTILIZING PREDICTABLY INACTIVATED PATHOGENSNovember 2022February 2024Allow1421YesNo
17821694STABILIZED SOLUBLE PRE-FUSION RSV F POLYPEPTIDESAugust 2022October 2024Abandon2510NoNo
17800296SYSTEMS AND METHODS FOR DETERMINING VIRUSES SUCH AS CORONAVIRUSESAugust 2022February 2024Allow1830YesNo
17883833RAPID DETECTION TEST FOR SARS-COV-2August 2022August 2023Allow1911NoNo
17861189VACCINES AGAINST HEPATITIS B VIRUSJuly 2022October 2023Allow1610NoNo
17857534Oncolytic Poliovirus for Human TumorsJuly 2022August 2023Allow1310NoNo
17848205RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAMEJune 2022February 2023Allow820NoNo
17848176RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAMEJune 2022February 2023Allow820NoNo
17750470COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCYMay 2022May 2023Allow1210NoNo
17664290VACCINE AGAINST RSVMay 2022July 2023Allow1410NoNo
17715741PHARMACEUTICAL AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SARS-COV-2April 2022February 2023Abandon1010NoNo
17681206PREVENTION OF VIRAL TRANSMISSION BY NAKED GENETIC MATERIALFebruary 2022March 2023Allow1320YesNo
17677399METHODS FOR IMMUNIZING PRE-IMMUNE SUBJECTS AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV)February 2022July 2023Allow1710YesNo
17636469SALIVA-BASED MOLECULAR TESTING FOR SARS-COV-2February 2022August 2022Allow600NoNo
17668287CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINSFebruary 2022November 2023Allow2110NoNo
17592333NEWCASTLE DISEASE VIRUS-BASED VECTORED VACCINEFebruary 2022September 2023Abandon1910NoNo
17585981ANTI-RESPIRATORY SYNCYTIAL VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USEJanuary 2022June 2024Allow2821NoNo
17579879METHOD FOR THE SAFE INDUCTION OF IMMUNITY AGAINST RSVJanuary 2022May 2023Allow1610NoNo
17577704METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST RSV INFECTIONJanuary 2022May 2023Allow1610NoNo
17564962RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAMEDecember 2021September 2023Allow2110YesNo
17556413SARS-COV-2 VIRUSES AND METHODS OF USE THEREOFDecember 2021July 2022Allow710NoNo
17544293ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USEDecember 2021May 2023Allow1710NoNo
17525775METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENTNovember 2021August 2023Allow2141YesNo
17524380PREFUSION RSV F PROTEINS AND THEIR USENovember 2021September 2023Allow2201YesNo
17451955RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOFOctober 2021January 2023Allow1500NoNo
17502785METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINEOctober 2021June 2023Allow2010NoNo
17499495NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOFOctober 2021June 2023Allow2010NoNo
17485705INFLUENZA HEMAGGLUTININ PROTEINS AND METHODS OF USE THEREOFSeptember 2021June 2023Abandon2010NoNo
17478533PREFUSION RSV F PROTEINS AND THEIR USESeptember 2021August 2024Abandon3521NoNo
17473972AVIAN INFLUENZA AND FOWL ADENOVIRUS TYPE 4 BI-COMBINED GENETIC ENGINEERING SUBUNIT VACCINE AND METHOD FOR PREPARING THE SAMESeptember 2021February 2022Allow600NoNo
17393328Peptides for Covid-19 Prevention and TreatmentAugust 2021February 2024Allow3120NoNo
17332901CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINSMay 2021January 2024Allow3210NoNo
17314649PRE-FUSION RSV F ANTIGENSMay 2021June 2023Abandon2510NoNo
17226690ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USEApril 2021October 2021Allow610NoNo
17210409ENGINEERING OF DENDRITIC CELLS FOR GENERATION OF VACCINES AGAINST SARS-COV-2March 2021May 2022Abandon1311NoNo
17196846IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS OF PRODUCTION FOR CORONAVIRUSMarch 2021May 2022Abandon1411NoNo
17173617MOUSE-ADAPTED SARS-COV-2 VIRUSES AND METHODS OF USE THEREOFFebruary 2021November 2021Allow911YesNo
17170876Composition and Method of mRNA Vaccines Against Novel Coronavirus InfectionFebruary 2021February 2024Allow3611NoNo
17265267INTRANASAL VACCINE THAT INDUCES CELLULAR IMMUNITYFebruary 2021October 2022Allow2110NoNo
17155953VACCINATION AGAINST CORONAVIRUS WITH POLIOMYELITIS VACCINEJanuary 2021June 2022Abandon1730NoNo
17262263ATTENUATED VIRUS STRAIN AND USE THEREOF AS A VACCINEJanuary 2021August 2022Allow1810YesNo
17261828NIPAH VIRUS IMMUNOGENS AND THEIR USEJanuary 2021September 2023Allow3201YesNo
17140383Test Kit For Detecting A Plurality Of AnalytesJanuary 2021May 2024Abandon4020NoNo
17126128Stabilized Soluble Pre-Fusion RSV F PolypeptidesDecember 2020September 2022Abandon2110NoNo
17080224COLD-ADAPTED LIVE ATTENUATED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS AND VACCINE CONTAINING THE SAMEOctober 2020March 2021Allow510YesNo
17078704RESPIRATORY SYNCYTIAL VIRUS VACCINEOctober 2020March 2023Abandon2920NoNo
17049916CHIMERIC VECTORSOctober 2020April 2024Allow4221NoNo
17070664RECOMBINANT TURKEY HERPESVIRUS VACCINES AND USES THEREOFOctober 2020April 2022Allow1810NoNo
17065514Peptides for Covid-19 Prevention and TreatmentOctober 2020May 2021Allow710YesNo
17061136Ferritin ProteinsOctober 2020November 2023Allow3711NoNo
17028288METHODS FOR IMMUNIZING PRE-IMMUNE SUBJECTS AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV)September 2020June 2022Abandon2010NoNo
17025568RECOMBINANT RSV WITH SILENT MUTATIONS, VACCINES, AND METHODS RELATED THERETOSeptember 2020June 2022Allow2110NoNo
17025110TREATMENTS TO ELIMINATE HIV RESERVOIRS AND REDUCE VIRAL LOADSeptember 2020November 2022Abandon2620NoNo
16981439COMPOSITIONS AND METHODS FOR VACCINATION AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTIONSeptember 2020November 2022Allow2620YesNo
17016699Oncolytic Poliovirus for Human TumorsSeptember 2020March 2022Allow1810NoNo
17015905VACCINE COMPOSITIONSeptember 2020May 2022Abandon2010NoNo
16977327METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZASeptember 2020December 2022Allow2711NoNo
16971020ANTI-VIRAL PROTEINSAugust 2020March 2024Abandon4301NoNo
16941394ANTIBODIES THAT POTENTLY NEUTRALIZE RSV AND USES THEREOFJuly 2020February 2022Allow1910NoNo
16964118STABILIZED RSV F PROTEINS AND USES THEREOFJuly 2020September 2022Allow2610NoNo
16920089MAMMARY TUMOR VIRUS SUPPRESSIONJuly 2020May 2024Allow4651YesYes
16946485VACCINE AGAINST RSVJune 2020January 2022Allow1910YesNo
16901993COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCYJune 2020January 2022Allow1910NoNo
16893706STABILIZED LIQUID LIVE VACCINEJune 2020May 2023Allow3530YesNo
16892132METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCESJune 2020August 2021Allow1511NoNo
16885009ANTIBODIES THAT NEUTRALIZE RSV, MPV AND PVM AND USES THEREOFMay 2020April 2022Allow2210NoNo
15931654SUPERHUMAN ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOFMay 2020February 2021Allow911YesNo
15931649ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM CR3022May 2020February 2021Allow911YesNo
15931643ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM 2GHWMay 2020February 2021Allow911YesNo
16763497RECOMBINANT RSV G PROTEINS AND THEIR USEMay 2020October 2023Allow4111NoNo
16864454RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOFMay 2020April 2021Allow1120NoNo
16760565ADENOVIRUS VECTORS AND USES THEREOFApril 2020June 2022Allow2500NoNo
16646363METHOD FOR DETECTING ACUTE BORNA DISEASE VIRUS (BDV) INFECTIONS, AND DIAGNOSTIC KIT THEREFOR, IN PARTICULAR IN COMBINATION WITH METHODS FOR DISTINGUISHING ACUTE FROM CHRONIC AND LATENT BDV INFECTIONS, AND DIAGNOSTIC KITS THEREFORApril 2020July 2023Allow4020YesNo
16755805BIOSENSOR FOR DETECTING INFLUENZA A VIRUS USING AU-FE3O4 COMPOSITEApril 2020September 2022Allow2910NoNo
16845930METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINEApril 2020January 2022Abandon2220YesNo
16649271Mutated Glycoprotein of Vesicular Stomatitis VirusMarch 2020June 2024Allow5122NoNo
16647758VACCINES AND METHODS OF MAKING AND USING VACCINES FOR PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONSMarch 2020April 2024Abandon4940YesNo
16801696COMPOSITIONS AND METHODS FOR TREATMENT IN BROAD-SPECTRUM, UNDIFFERENTIATED OR MIXED CLINICAL APPLICATIONSFebruary 2020May 2022Abandon2720NoNo
16642082METHOD FOR THE SAFE INDUCTION OF IMMUNITY AGAINST RSVFebruary 2020September 2021Allow1810NoNo
16786954TREATMENT OF HUMAN METAPNEUMOVIRUSFebruary 2020January 2022Abandon2420NoYes
16638072DIFFERENTIAL COATING OF MICROPROJECTIONS AND MICRONEEDLES ON ARRAYSFebruary 2020August 2023Abandon4220NoYes
16637155CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINSFebruary 2020October 2021Allow2000YesNo
16752328COMBINATION OF IMMUNO-ONCOLYTIC VIRUS DRUGS FOR ENHANCING SYSTEMIC IMMUNE RESPONSE AND APPLICATION THEREOFJanuary 2020March 2024Abandon5021NoNo
16742036ANTIBODY, COMPOSITE, DETECTION DEVICE AND METHOD USING SAMEJanuary 2020November 2021Allow2210NoNo
16739890VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODSJanuary 2020December 2021Abandon2320NoNo
16630421METHOD FOR PRESERVING BIOPHARMACEUTICALSJanuary 2020April 2022Allow2701NoNo
16730429VIRUS CAUSING RESPIRATORY TRACT ILLNESS IN SUSCEPTIBLE MAMMALSDecember 2019June 2021Allow1820NoNo
16721229HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDEDecember 2019December 2022Allow3621YesNo
16620829METHOD FOR EVALUATING SEVERITY OF DENGUE VIRUS INFECTION IN INDIVIDUAL, DETECTION DEVICE AND DETECTIONDecember 2019September 2023Abandon4530NoNo
16696943RECOMBINANT TURKEY HERPESVIRUS VACCINES AND USES THEREOFNovember 2019June 2020Allow710NoNo
16616876NANOSTRUCTURE WITH A NUCLEIC ACID SCAFFOLD AND VIRUS-BINDING PEPTIDE MOIETIESNovember 2019October 2023Abandon4640NoNo
16615372SIMULTANEOUS IN VITRO ANALYSIS OF VACCINE POTENCY AND TOXIN CONCENTRATIONNovember 2019July 2023Abandon4411NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HILL, MYRON G.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
5
(71.4%)
Examiner Reversed
2
(28.6%)
Reversal Percentile
43.0%
Lower than average

What This Means

With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
78
Allowed After Appeal Filing
17
(21.8%)
Not Allowed After Appeal Filing
61
(78.2%)
Filing Benefit Percentile
25.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 21.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HILL, MYRON G - Prosecution Strategy Guide

Executive Summary

Examiner HILL, MYRON G works in Art Unit 1648 and has examined 682 patent applications in our dataset. With an allowance rate of 53.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner HILL, MYRON G's allowance rate of 53.1% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HILL, MYRON G receive 2.10 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HILL, MYRON G is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +30.7% benefit to allowance rate for applications examined by HILL, MYRON G. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.4% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 44.9% of cases where such amendments are filed. This entry rate is in the 63% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 46% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 79.4% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 88.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 56.7% are granted (fully or in part). This grant rate is in the 72% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.7% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.8% of allowed cases (in the 86% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.